There are another four FDA-approved drugs: dacomitinib (which targets mutant EGFR in lung cancer), neratinib (which targets ErbB2 in HER2-positive lung cancer), osimertinib (which targets EGFR T970M mutants in NSCLC), and ibrutinib (which targets BTK in mantle cell lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, and chronic graft vs. host. This evidence concerns the gene ERBB2 and mantle cell lymphoma.